Perrigo (PRGO) Capital Expenditures (2013 - 2026)
Perrigo's (PRGO) quarterly Capital Expenditures came in at $13.8 million in Q1 2026, down 45.88% year-on-year from $25.5 million in Q1 2025, and down 48.51% on a QoQ basis from $26.8 million in Q4 2025.
Perrigo (PRGO) Capital Expenditures (2013 - 2026) Analysis & Trends
Perrigo (PRGO) has 14 years of Capital Expenditures data on file, last reported at $13.8 million in Q1 2026.
- On a quarterly basis, Capital Expenditures fell 45.88% year-over-year to $13.8 million in Q1 2026; TTM through Mar 2026 was $81.7 million, a 31.17% decrease from a year earlier, with the FY2025 full-year figure at $93.4 million, down 21.05% from the prior year.
- Capital Expenditures for Q1 2026 stood at $13.8 million, down from $26.8 million in the prior quarter.
- Over the last five years, Capital Expenditures for PRGO reached as high as $86.1 million in Q4 2022 and fell as low as -$38.4 million in Q4 2022.
- Historically, Capital Expenditures has averaged $24.9 million across 5 years, with a median of $25.5 million in 2025.
- Across the five-year window, Capital Expenditures slumped 1845.45% in 2022 and jumped 182.81% in 2023, its largest moves.
- Year by year, Capital Expenditures stood at $86.1 million in 2022, then sank by 68.99% to $26.7 million in 2023, then surged by 41.2% to $37.7 million in 2024, then declined by 28.91% to $26.8 million in 2025, then tumbled by 48.51% to $13.8 million in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were $13.8 million in Q1 2026, $26.8 million in Q4 2025, and $21.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.05 Bn | 325.50 Mn | 13.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 13.80 Mn |
| Mar 28, 2026 | 13.80 Mn |
| Dec 31, 2025 | 26.80 Mn |
| Dec 31, 2025 | 26.80 Mn |
| Sep 27, 2025 | 21.90 Mn |
| Sep 27, 2025 | 21.90 Mn |
| Jun 28, 2025 | 19.20 Mn |
| Jun 28, 2025 | 19.20 Mn |
| Mar 29, 2025 | 25.50 Mn |
| Mar 29, 2025 | 25.50 Mn |
| Dec 31, 2024 | 37.70 Mn |
| Dec 31, 2024 | 37.70 Mn |
| Sep 28, 2024 | 27.10 Mn |
| Sep 28, 2024 | 27.10 Mn |
| Jun 29, 2024 | 28.40 Mn |
| Jun 29, 2024 | 28.40 Mn |
| Mar 30, 2024 | 25.10 Mn |
| Mar 30, 2024 | 25.10 Mn |
| Dec 31, 2023 | 26.70 Mn |
| Dec 31, 2023 | 26.70 Mn |